Skip to content
MamaGLP — home
Menu

Evidence review

The Next Generation of GLP-1s, Explained (Warmly)

A plain-language, cited primer on what's coming next in GLP-1s — oral semaglutide, orforglipron, retatrutide, and CagriSema — for curious moms.

Written by Camila Rael, editor

Research checked by Beatriz Lang, our evidence reviewer — a former pharma-industry analyst (a disclosed pen name), not a clinician who treats you. What follows is friendly information, never medical advice.

The friendly overview

If you have heard names like "the pill version" or "the triple one" and felt a little lost, this page is for you. The GLP-1 world is moving fast, and a few new options are coming that could make treatment easier to take or more effective. None of this changes what you should do today — that is still a conversation with your clinician — but it is genuinely nice to know where things are headed. For a baseline, today's benchmark injectable semaglutide helped adults lose close to 15% of their body weight over 68 weeks in its landmark trial1. Keep that number in your back pocket as we go, so the new arrivals have something to be compared against. And if any term trips you up, GLP-1 basics for first-timers is a gentle glossary.

The pill you swallow: oral semaglutide

The headline most moms care about: a **once-daily tablet**, no injection. Higher-dose oral semaglutide has been tested for weight loss, and in the OASIS 1 trial the 50 mg tablet led to about **15% body-weight loss at 68 weeks** versus about 2% on placebo2. A newer trial of a **25 mg** tablet found roughly **14%** loss3 — a slightly gentler dose in the same family. The trade-off to know: like the injections, the tablets bring gastrointestinal side effects (nausea, etc.) more often than placebo, and the tablet has particular timing rules for how you take it. But for anyone whose main hesitation is needles, a pill in the same efficacy neighborhood as the injection is a meaningful "coming soon."

The other pill, built differently: orforglipron

**Orforglipron** is also an oral GLP-1, but it is a small-molecule drug — chemically simpler to make than semaglutide, without the strict food-and-water timing rules, which is why a lot of people are watching it. In a large 72-week trial, its higher dose put **more than half of participants past 10% body-weight loss**, with a side-effect profile in line with other GLP-1 medicines4. It is a touch earlier in the story than oral semaglutide, but the promise — an easy-to-manufacture daily pill — is exactly why you keep hearing the name.

The heavy hitter: retatrutide

**Retatrutide** is a "triple agonist" — it acts on three hormone pathways at once (GLP-1 plus GIP plus glucagon) instead of one or two. In a phase 2 trial, its highest dose produced around **24% body-weight loss at 48 weeks**5 — the largest figures we have seen in this class so far. The honest caveats: this is still earlier-stage research, larger and longer trials are underway, and bigger appetite effects can come with more side effects to manage. But if you have wondered "how far can this go," retatrutide is the reason the ceiling keeps rising.

The combo: CagriSema

**CagriSema** pairs semaglutide with a second molecule, **cagrilintide** (an amylin-based drug), in one weekly injection — the idea being two complementary appetite pathways working together. In its phase 3 REDEFINE 1 trial, CagriSema produced about **20% body-weight loss at 68 weeks** versus roughly 3% on placebo6. So it lands above today's single-agent semaglutide, in the same conversation as the triple agonist, as a combination approach.

How to hold all of this

A simple way to file it away: **oral semaglutide** and **orforglipron** are about *convenience* (a pill instead of a shot); **retatrutide** and **CagriSema** are about *more* (bigger results by hitting more pathways). Availability, insurance coverage, and approval timelines vary and keep shifting, so the right question for your clinician is never "which future drug" but "what is the best option *for me, right now*." The pipeline is a reason for optimism, not a reason to wait.

A warm next step

You do not need a pharmacology degree to make a good decision — you need a clinician who knows the current options and a starting point that fits your life. When you are ready to compare what is actually available today, our best GLP-1 for moms board lays it out plainly, and our top pick CoreAge Rx is a low-pressure place to see what a thoughtful program looks like. To keep learning, GLP-1 myths vs. facts is a great companion to this primer. The future is bright, and you get to meet it at your own pace. — Camila

*This guide is educational only and is not medical advice. Investigational medicines described here may not be approved or available in your area; approval and coverage change over time.*

Frequently asked questions

Is there a GLP-1 pill instead of an injection?

Yes — higher-dose oral semaglutide is a once-daily tablet, and in the OASIS 1 trial the 50 mg dose produced about 15% body-weight loss at 68 weeks. Orforglipron is another daily oral GLP-1, chemically simpler and without strict timing rules. Availability and approval vary, so ask your clinician what is offered where you are.

What is retatrutide and why do people say it works so well?

Retatrutide is a 'triple agonist' that acts on three hormone pathways at once (GLP-1, GIP, and glucagon). In a phase 2 trial its highest dose produced around 24% body-weight loss at 48 weeks — the largest figures in the class so far. It is still earlier-stage, with bigger trials underway.

What is CagriSema?

CagriSema is a once-weekly injection combining semaglutide with cagrilintide, an amylin-based molecule, so two appetite pathways work together. In its phase 3 REDEFINE 1 trial it produced about 20% body-weight loss at 68 weeks versus roughly 3% on placebo.

Should I wait for these newer medicines before starting?

Not necessarily. Availability, coverage, and approval timelines keep shifting, and today's options are effective and well studied. The better question for your clinician is what is the best choice for you right now — the pipeline is a reason for optimism, not a reason to delay.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Knop FK, Aroda VR, do Vale RD, et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://pubmed.ncbi.nlm.nih.gov/37385278/
  3. Wharton S, et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40934115/
  4. Wharton S, et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40960239/
  5. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/37366315/
  6. Garvey WT, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40544433/

Friendly information, not a prescription. Everything on MamaGLP is here to help you understand your options and ask better questions — it isn't a diagnosis, a treatment plan, or a nudge to start or stop anything. Only a licensed clinician who knows your history and your goals can tell you what's right for you, so please loop one in before you act on a word of it.

Continue reading